AZNCF - Cellectis: 2 Data Readouts Of Blood Cancer Studies By End Of 2024

2024-05-30 09:14:24 ET

Summary

• Data update from phase 1 BALLI-01 study, using UCART22 for the treatment of B-cell acute lymphoblastic leukemia, expected by the end of 2024.
• The global acute lymphoblastic leukemia therapeutics market is expected to increase to $8.29 billion by 2032.
• Data update from phase 1/2 NATHALI-01 study, using UCART20x22 for the treatment of patients with B-cell non-Hodgkin lymphoma, expected by the end of 2024.
• The global non-Hodgkin lymphoma market is expected to reach $11 billion by 2029.

Cellectis ( CLLS ) is an important biotech to watch because it is advancing several programs in its pipeline which are being used to treat patients with hematological malignancies. The reason why I believe that it is important to highlight this biotech next is because it is expected to have two data readouts by the end of 2024. These are going to be huge inflection points for it, and the hope is that the results from both of these studies will turn out to be positive. The first catalyst of which involves the use of UCART22 for the treatment of patients with relapsed/refractory acute lymphoblastic leukemia [r/r ALL] in the ongoing BALLI-01 study. The second catalyst of which involves the use of UCART20x22 for the treatment of patients with relapsed or refractory B-cell non-Hodgkin lymphoma [r/r B-NHL]....

For further details see: